Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (493) 493
Publication (52) 52
Book Review (11) 11
Book Chapter (8) 8
Conference Proceeding (2) 2
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vedolizumab (483) 483
index medicus (249) 249
ulcerative colitis (245) 245
maintenance therapy (241) 241
inflammatory bowel disease (218) 218
gastroenterology & hepatology (198) 198
crohn's disease (178) 178
infliximab (154) 154
humans (151) 151
ulcerative-colitis (144) 144
crohns-disease (140) 140
induction (120) 120
inflammatory-bowel-disease (109) 109
adalimumab (92) 92
antibodies, monoclonal, humanized - therapeutic use (84) 84
induction therapy (75) 75
crohn’s disease (71) 71
natalizumab (69) 69
colitis, ulcerative - drug therapy (64) 64
gastrointestinal agents - therapeutic use (63) 63
crohn disease - drug therapy (60) 60
male (59) 59
female (58) 58
pharmacology & pharmacy (57) 57
ustekinumab (57) 57
inflammatory bowel diseases (54) 54
adult (52) 52
remission (49) 49
inflammatory bowel diseases - drug therapy (47) 47
management (46) 46
treatment outcome (46) 46
integrin (42) 42
antibodies, monoclonal, humanized - adverse effects (41) 41
safety (40) 40
therapy (40) 40
tumor necrosis factor-alpha - antagonists & inhibitors (40) 40
gastroenterology (39) 39
care and treatment (38) 38
golimumab (38) 38
middle aged (37) 37
efficacy (36) 36
immunology (34) 34
patients (34) 34
anti-tnf (32) 32
combination therapy (31) 31
tofacitinib (31) 31
biologics (30) 30
gastrointestinal agents - adverse effects (30) 30
integrins (30) 30
progressive multifocal leukoencephalopathy (30) 30
analysis (29) 29
double-blind (29) 29
animals (28) 28
medicine & public health (28) 28
azathioprine (27) 27
medical research (26) 26
monoclonal antibodies (26) 26
remission induction (26) 26
monoclonal-antibody (25) 25
clinical trials (24) 24
tumor necrosis factor (24) 24
active crohns-disease (23) 23
colon (23) 23
drug therapy (23) 23
medicine, general & internal (23) 23
surgery (23) 23
certolizumab pegol (22) 22
clinical-response (22) 22
integrins - antagonists & inhibitors (22) 22
tumor necrosis factor-tnf (22) 22
article (21) 21
colitis (21) 21
corticosteroids (21) 21
young adult (21) 21
anti-tnf therapy (20) 20
crohns disease (20) 20
evidence-based consensus (20) 20
medicine, experimental (20) 20
pharmacokinetics (20) 20
systematic review (20) 20
abridged index medicus (19) 19
antibodies, monoclonal, humanized - pharmacology (19) 19
endoscopy (19) 19
health aspects (19) 19
humanized antibody (19) 19
ibd (19) 19
intestine (19) 19
original (19) 19
retrospective studies (19) 19
severity of illness index (19) 19
antibody (18) 18
biological products (18) 18
outcomes (18) 18
risk (18) 18
antibodies, monoclonal - therapeutic use (17) 17
biological therapy (17) 17
etrolizumab (17) 17
gastroenterology and hepatology (17) 17
inflammation (17) 17
madcam-1 (17) 17
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (459) 459
German (17) 17
Spanish (12) 12
Czech (6) 6
French (4) 4
Russian (3) 3
Korean (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Exclusive antagonism of the α 4 β 7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
by Fedyk, Eric R and Wyant, Tim and Yang, Li-Li and Csizmadia, Vilmos and Burke, Kristine and Yang, Hua and Kadambi, Vivek J
Inflammatory Bowel Diseases, ISSN 1078-0998, 11/2012, Volume 18, Issue 11, pp. 2107 - 2119
MLN0002 | MLN02 | vedolizumab | LDP-02
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Simultaneous inhibition of alpha 4/beta 7 integrin and tumour necrosis factor-alpha in concomitant spondyloarthritis and inflammatory bowel disease
by Richard, N and Hazel, EM and Haroon, N and Inman, RD
ANNALS OF THE RHEUMATIC DISEASES, ISSN 0003-4967, 12/2018, Volume 77, Issue 12
COMBINATION THERAPY | RHEUMATOLOGY | VEDOLIZUMAB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
by Singh, Siddharth and Facciorusso, Antonio and Dulai, Parambir S and Jairath, Vipul and Sandborn, William J
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, ISSN 1542-3565, 03/2019
We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Improving Clinical Trial Efficiency in Gastroenterology Reply
by Harris, MS and Howden, CW
GASTROENTEROLOGY, ISSN 0016-5085, 09/2019, Volume 157, Issue 3, pp. 894 - 894
INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | VEDOLIZUMAB | MAINTENANCE THERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review
by Estevinho, Maria Manuela and Rocha, Cátia and Correia, Luís and Lago, Paula and Ministro, Paula and Portela, Francisco and Trindade, Eunice and Afonso, Joana and Peyrin-Biroulet, Laurent and Magro, Fernando
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2019
Background & AimsWe performed a systematic review of changes in fecal and colon microbiomes of patients with inflammatory bowel diseases (IBD) receiving... 
Gastroenterology and Hepatology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Comment on: 'Resolution of CMV Infection in the Bowel on Vedolizumab Therapy'
by Hommel, C and Pillet, S and Rahier, J-F
Journal of Crohn's & colitis, ISSN 1873-9946, 06/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The 4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells in Vivo
by Zundler, Sebastian and Fischer, Anika and Schillinger, Daniela and Binder, Marie-Theres and Atreya, Raja and Rath, Timo and Lopez-Pósadas, Rocío and Voskens, Caroline J and Watson, Alastair and Atreya, Imke and Neufert, Clemens and Neurath, Markus F
Inflammatory Bowel Diseases, ISSN 1078-0998, 03/2017, Volume 23, Issue 3, pp. 379 - 391
vedolizumab | inflammatory bowel diseases | gut homing | T cells | natalizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
by Yarur, Andres J and Bruss, Alexandra and Naik, Snehal and Beniwal-Patel, Poonam and Fox, Caroline and Jain, Anjali and Berens, Brandon and Patel, Amir and Ungaro, Ryan and Bahur, Bayda and Dubinsky, Marla and Stein, Daniel J
Digestive Diseases and Sciences, ISSN 0163-2116, 6/2019, Volume 64, Issue 6, pp. 1651 - 1659
The aim of this study was to assess the relationship of serum vedolizumab concentrations (SVC) during induction and endoscopic remission in patients with... 
Biochemistry, general | Anti-vedolizumab antibodies | Oncology | Mucosal healing | Transplant Surgery | Therapeutic drug monitoring | Vedolizumab levels | Medicine & Public Health | Hepatology | Gastroenterology | Vedolizumab | Crohn’s disease | Ulcerative colitis | SCORE | CROHNS-DISEASE | ULCERATIVE-COLITIS | VALIDATION | Crohn's disease | INDUCTION | MAINTENANCE THERAPY | TROUGH LEVELS | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | Viral antibodies | Medical colleges | Medical research | Care and treatment | Biological products | Albumin | Medicine, Experimental | Antibodies | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The alpha 4 beta 1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo
by Zundler, S and Fischer, A and Schillinger, D and Binder, MT and Atreya, R and Rath, T and Lopez-Posadas, R and Voskens, CJ and Watson, A and Atreya, I and Neufert, C and Neurath, MF
INFLAMMATORY BOWEL DISEASES, ISSN 1078-0998, 03/2017, Volume 23, Issue 3, pp. 379 - 391
Background: The precise mechanisms controlling homing of T effector (Teff) cells to the inflamed gut in Crohn's disease (CD) are still unclear, and clinical... 
vedolizumab | VEDOLIZUMAB INDUCTION THERAPY | inflammatory bowel diseases | ULCERATIVE-COLITIS | SMALL-INTESTINE | T cells | MAINTENANCE THERAPY | ADHESION MOLECULE-1 | INFLAMMATORY-BOWEL-DISEASE | gut homing | BINDING-SITES | META-ANALYSIS | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-PRACTICE | natalizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases
by Ungar, Bella and Kopylov, Uri and Yavzori, Miri and Fudim, Ella and Picard, Orit and Lahat, Adi and Coscas, Daniel and Waterman, Matti and Haj-Natour, Ola and Orbach-Zingboim, Noam and Mao, Ren and Chen, Minhu and Chowers, Yehuda and Eliakim, Rami and Ben-Horin, Shomron
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 05/2018, Volume 16, Issue 5, pp. 697 - 705.e7
There are few data available on the real-life pharmacokinetic and pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We... 
Clinical Outcome | Trough Level | IBD | Clinical Response | Vedolizumab | Immunogenicity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Eficacia y seguridad de vedolizumab como opción terapéutica en colitis ulcerosa moderada-grave refractaria en dos pacientes trasplantados hepáticos por colangitis esclerosante primaria
by Olmedo-Martín, Raúl Vicente and Amo-Trillo, Víctor and González-Grande, Rocío and Jiménez-Pérez, Miguel
Revista Espanola de Enfermedades Digestivas, ISSN 1130-0108, 09/2017, Volume 109, Issue 9, pp. 659 - 662
Liver transplant | Vedolizumab | Ulcerative colitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Response to: 'Simultaneous inhibition of alpha 4/beta 7 integrin and tumor necrosis factor-alpha in concomitant spondyloarthritis and inflammatory bowel disease' by Richard et al
by Varkas, G and Elewaut, D
ANNALS OF THE RHEUMATIC DISEASES, ISSN 0003-4967, 12/2018, Volume 77, Issue 12
CROHNS-DISEASE | INDUCTION | RHEUMATOLOGY | VEDOLIZUMAB | NETWORK METAANALYSIS | MAINTENANCE THERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3
by Sands, Bruce E and Van Assche, Gert and Tudor, David and Akhundova-Unadkat, Gamar and Curtis, Rebecca I and Tan, Tjoeke
Inflammatory Bowel Diseases, ISSN 1078-0998, 07/2019, Volume 25, Issue 8, pp. 1375 - 1382
Abstract Background Combined therapy with vedolizumab and corticosteroids may improve clinical response or remission in Crohn’s disease. The aim of this study... 
Original Clinical | vedolizumab | induction | corticosteroids | Crohn’s disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Anti-integrin therapy for inflammatory bowel disease
by Park, Sung Chul and Jeen, Yoon Tae
World Journal of Gastroenterology, ISSN 1007-9327, 05/2018, Volume 24, Issue 17, pp. 1868 - 1880
In inflammatory bowel disease (IBD), tumor necrosis factor plays an important role in mediating inflammation, but several other pathways are also involved in... 
Inflammatory bowel disease | Abrilumab | Integrin | Natalizumab | Etrolizumab | Vedolizumab | PF00547659 | AJM300 | Crohn’s disease | Ulcerative colitis | VEDOLIZUMAB INDUCTION THERAPY | ANTAGONIST | EFFICACY | PF-00547659 | ULCERATIVE-COLITIS | Crohn's disease | ACTIVE CROHNS-DISEASE | MAINTENANCE THERAPY | ENDOTHELIAL-CELLS | DOUBLE-BLIND | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | Minireviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Nodular Vasculitis in a Patient With Crohn’s Disease on Vedolizumab
by Pouldar, Delila and Elsensohn, Ashley and Ortenzio, Francesca and Shiu, Jessica and McLeod, Michael and de Feraudy, Sébastien
The American Journal of dermatopathology, ISSN 0193-1091, 3/2018, Volume 40, Issue 3, pp. e36 - e37
Erythema induratum (EI), or nodular vasculitis (NV), is a type of panniculitis that is often associated with vasculitis affecting various-sized veins, venules,... 
vedolizumab | erythema induratum | nodular vasculitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Risk of Postoperative Surgical Site Infections after Vedolizumab versus Anti-Tumor Necrosis Factor Therapy: A Propensity-Score Matching Analysis in Inflammatory Bowel Disease
by Park, KT and Sceats, Lindsay and Dehghan, Melody and Trickey, Amber W and Wren, Anava and Wong, Jessie J and Bensen, Rachel and Limketkai, Berkeley N and Keyashian, Kian and Kin, Cindy
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 8/2018, Volume 48, Issue 3, pp. 340 - 346
Inflammatory bowel disease | postoperative complications | vedolizumab | biologic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients
by Lightner, Amy L and McKenna, Nicholas P and Alsughayer, Ahmad and Loftus, Edward V and Raffals, Laura E and Faubion, William A and Moir, Christopher
Journal of Pediatric Surgery, ISSN 0022-3468, 10/2019, Volume 54, Issue 10, pp. 2162 - 2165
Limited knowledge exists as to what impact preoperative biologic therapy has on postoperative complications in pediatric patients undergoing abdominal surgery... 
Anti-TNF | Ustekinumab | Crohn's disease | Vedolizumab | Postoperative outcomes | SURGERY | VEDOLIZUMAB INDUCTION THERAPY | ILEOCOLONIC RESECTION | ULCERATIVE-COLITIS | ALPHA | RISK | INFLIXIMAB THERAPY | ABDOMINAL-SURGERY | INFLAMMATORY-BOWEL-DISEASE | PEDIATRICS | COMPLICATIONS | OUTCOMES | Monoclonal antibodies | Pediatrics | Children | Tumor necrosis factor | Health aspects | Morbidity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Treat to targetwhat is realistic in Australian practice today?
by Gearry, RB
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, ISSN 0815-9319, 06/2016, Volume 31, pp. 4 - 5
INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | VEDOLIZUMAB | MAINTENANCE THERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2
by Feagan, Brian G and Schwartz, David and Danese, Silvio and Rubin, David T and Lissoos, Trevor W and Xu, Jing and Lasch, Karen
Journal of Crohn's and Colitis, ISSN 1873-9946, 04/2018, Volume 12, Issue 5, pp. 621 - 626
Abstract Background and Aims Medical management of fistulising Crohn’s disease [CD] is constrained by the limited number of available therapies. We evaluated... 
Short Report | Vedolizumab | fistula | Crohn’s disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Arthrits occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report
by Wendling, D and Sondag, M and Verhoeven, F and Vuitton, L and Koch, S and Prati, C
JOINT BONE SPINE, ISSN 1297-319X, 03/2018, Volume 85, Issue 2, pp. 255 - 256
Spondyloarthrits | Inflammatory bowel disease | GUT | Arthritis | Vedolizumab | RHEUMATOLOGY | INFLIXIMAB | MANIFESTATIONS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.